KineMed, Inc. Receives Enabling Technology Award for Pathway Based Drug Discovery From Frost & Sullivan
Published: Nov 13, 2012
EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed, Inc. (www.kinemed.com) announced today that it has been awarded the prestigious Frost & Sullivan 2012 North American Enabling Technology Award for Pathway Based Drug Discovery. KineMed’s novel biomarkers facilitate development of evidence based medicines and diagnostics for complex diseases. The company uses proprietary mass spectroscopy methods that measure flux in proteins and metabolites in vivo.